This seems like a golden age for those struggling with weight. The arrival of Ozempic, Wegovy, and other GLP-1 agonists is offering hope where there was none. It's also presenting employers across our country with a tough decision: how best to cover, or not to cover, such high-demand, high-cost drugs?
The headlines make it all sound so simple, an easy "yes, definitely," but the best counsel is actually to take a beat and zoom out. Before handing over the syringe, companies debating whether or not to cover for these medications should study the big picture first, and look at the facts as we know them.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
